1 NIH Consensus Conference. NIH Consensus Panel on Impotence. JAMA, 1993; 270: 83
2 郭应禄,主编.阴茎勃起功能障碍.第1 版.北京:北京医科大学出版社,1999; 1, 82, 90
3 Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial corre-lates: results of the massa chusetts male aging study. J Urol, 1994; 1 51: 54
4 Leng J. The prevalence of erectile dysfunction in elder men in shanghai (an analysis of1582 case s). Int J Impot Res, 1998; 1 0: 9
5 Karl-erik A, Gorm W. Physiology of penile erection. Phys Rev, 1995; 7 5(1):1 91
6 许士凯. 阴茎勃起生理.中国乡村医生, 1989; (12):3 6
7 陈浩宏, 许士凯.性功能的神经药理学研究进展.男性学杂志, 1990; 4(4):2 46
8 蒋晓刚, 徐衤氏顺.一氧化氮与阴茎的关系.男性学杂志, 1998; 12(1):57
9 Jackson SE, Lue TF. Erectile dysfunction: therapy health outcomes. J Urol, 1998; 5 1 (6):874
10 Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of go al directed therapy for impotence. J Urol, 1996; 1 55: 1609
11 马永江. 阴茎勃起障碍的药物治疗进展.男性学杂志1996; 10(4):2 33
12 许士凯.性药学. 第1 版.上海:上海中医学院出版社,1989: 266
13 许士凯. 药物对男性性功能的影响.见:黄平治, 等.男性性功能障碍.北京:科学技术文献出版社, 1992: 253
14 马培奇. 阳痿治疗药物的现状及其进展.中国医药情报1998; 1(5):268
15 许士凯. 当代性药学的研究进展与展望.亚洲医药杂志, 1995; 6(6):3 6
16 Phentolamine Mesilate. Drugs Future, 1998; 23(7): 725
17 田少富. 酚妥拉明的知识产权保护情况分析.医药知识产权通讯, 1998; (3):1 6
18 Boolell M, Gepi-Attee S, Gingell JC, et al. Sildnafil, a novel effective or al the rapy for male erectile dysfunction. Br J Urol, 1996; 7 8: 257
19 Morales A, Gingll C, Collins M, et al. Clinical safety of oral sildena fil citrate (VIAGRATM)in the treatment of erectile dysfunction. Int L Impot Res, 1998; 10: 6 91 |
